| Grab Sources And More Here: ATNM Website. -----
6 Immediate Potential Catalysts Could Paint Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) With A Breakout Target...
#1. Monday Afternoon's Major News Announcement: With an afternoon press release Monday, potentially under-the-radar going into Tuesday, Actinium Pharmaceuticals has secured a supply agreement with Eckert & Ziegler for Actinium-225, a critical radioisotope, to support the development of its lead product Actimab-A and other candidates for cancer treatment in U.S. and international clinical trials.
#2. Growing Chart Momentum: Since the beginning of March, ATNM has climbed more than 50% from a $1.02+ low to a $1.59 high.
With this move, ATNM has pushed above 4 key technical chart levels. If potential support grows at those levels, it could help ATNM maintain its recent green stretch this month.
#3. A Strong Analyst Target: Stephens, Inc. analyst, Sudan Loganathan, Ph.D., maintains an "Overweight" rating with a $5.00 target.
From it's 4:00PM EST closing valuation on Monday, ATNM may have over 200% potential upside to this target.
#4. A Highly Promising Research Collab: Actinium Pharmaceuticals has entered into a research collaboration with Memorial Sloan Kettering Cancer Center to expand the potential of Actimab-A, their lead radiotherapeutic for acute myeloid leukemia (AML).
The collaboration aims to study Actimab-A in combination with targeted therapies and assess its activity on patient-derived AML samples, with the goal of addressing unmet needs in myeloid malignancies and potentially improving patient outcomes.
#5. A Clinical Trial Announcement: Actinium Pharmaceuticals has announced a new clinical trial program combining Actimab-A with PD-1 checkpoint inhibitors KEYTRUDA® and OPDIVO® for solid tumors, focusing on Head and Neck Squamous Cell Carcinoma (HNSCC) and Non-Small Cell Lung Cancer (NSCLC).
The trials aim to improve patient outcomes by targeting Myeloid Derived Suppressor Cells (MDSCs) in the tumor microenvironment, with initial proof of concept clinical data expected in the second half of 2025.
#6. Initiation Of Combination Frontline Trial: Actinium Pharmaceuticals has initiated a Phase 1/2 clinical trial combining Actimab-A with Venetoclax and Azacitidine for relapsed or refractory acute myeloid leukemia (AML) under a Cooperative Research and Development Agreement with the National Cancer Institute.
The trial aims to evaluate safety, tolerability, and efficacy, leveraging Actimab-A's mutation-agnostic mechanism to improve treatment outcomes, with initial data expected in late 2025. -----
Coverage is officially initiated on Actinium Pharmaceuticals, Inc. (NYSE American: ATNM).
I'll be in touch with updates. Be on the lookout.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 03/25/2025 and ending on 03/25/2025 to publicly disseminate information about (ATNM:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (ATNM:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/atnm/#details | 
0 Response to "(NYSE American: ATNM) Puts The Pedal To The Metal, Surging Vertically Up Approx. 37%"
Post a Comment